. 2021 Mar 9;50(1):15.

doi: 10.1186/s40463-021-00493-2.

Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis

Andrew Thamboo¹, S Kilty², I Witterick³, Y Chan³, C J Chin⁴, A Janjua⁵, A Javer⁵, J Lee³, E Monterio³, B Rotenberg⁶, J Scott⁴, K Smith⁷, D D Sommer⁸, L Sowerby⁶, M Tewfik⁹, E Wright¹⁰, M Desrosiers¹¹

Affiliations

¹ Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of British Columbia, 2600-1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada. andrew.thamboo@gmail.com.
² Department of Otolaryngology-Head and Neck Surgery, The University of Ottawa and The Ottawa Hospital, Ottawa, ON, Canada.
³ Department of Otolaryngology-Head & Neck Surgery, University of Toronto, Toronto, ON, Canada.
⁴ Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Dalhousie University, Halifax, NS, Canada.
⁵ Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of British Columbia, 2600-1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada.
⁶ Department of Otolaryngology-Head and Neck Surgery, Western University, London, ON, Canada.
⁷ Department of Otolaryngology-Head and Neck Surgery, University of Manitoba, Winnipeg, MB, Canada.
⁸ Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, McMaster University, Hamilton, ON, Canada.
⁹ Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, QC, Canada.
¹⁰ Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada.
¹¹ Division of Otolaryngology-Head and Neck Surgery, Centre Hospitalier de l'University de Montreal, Montreal, QC, Canada.

PMID: 33750471
PMCID: PMC7945300
DOI: 10.1186/s40463-021-00493-2

Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis

Andrew Thamboo et al. J Otolaryngol Head Neck Surg. 2021.

. 2021 Mar 9;50(1):15.

doi: 10.1186/s40463-021-00493-2.

Authors

Affiliations

¹ Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of British Columbia, 2600-1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada. andrew.thamboo@gmail.com.
² Department of Otolaryngology-Head and Neck Surgery, The University of Ottawa and The Ottawa Hospital, Ottawa, ON, Canada.
³ Department of Otolaryngology-Head & Neck Surgery, University of Toronto, Toronto, ON, Canada.
⁴ Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Dalhousie University, Halifax, NS, Canada.
⁵ Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of British Columbia, 2600-1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada.
⁶ Department of Otolaryngology-Head and Neck Surgery, Western University, London, ON, Canada.
⁷ Department of Otolaryngology-Head and Neck Surgery, University of Manitoba, Winnipeg, MB, Canada.
⁸ Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, McMaster University, Hamilton, ON, Canada.
⁹ Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, QC, Canada.
¹⁰ Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada.
¹¹ Division of Otolaryngology-Head and Neck Surgery, Centre Hospitalier de l'University de Montreal, Montreal, QC, Canada.

PMID: 33750471
PMCID: PMC7945300
DOI: 10.1186/s40463-021-00493-2

Abstract

Background: Recent evidence suggests that biologic therapy with targeted activity within the Type 2 inflammatory pathway can improve the clinical signs and symptoms of chronic rhinosinusitis with nasal polyposis (CRSwNP). There remains a population in CRSwNP that despite medical therapy and endoscopic sinus surgery have persistent signs and symptoms of disease. Therefore, biologics, monoclonal antibody agents, could be beneficial therapeutic treatments for these patients. There have been eight randomized, double-blind, placebo-controlled trails performed for CRSwNP targeted components of the Type 2 inflammatory pathway, notably interleukin (IL)-4, IL-5 and IL-13, IL-5R, IL-33, and immunoglobulin (Ig)E. However, there are no formal recommendations for the optimal use of biologics in managing Chronic Rhinosinusitis (CRS) within the Canadian health care environment.

Methods: A Delphi Method process was utilized involving three rounds of questionnaires in which the first two were completed individually online and the third was discussed on a virtual platform with all the panelists. 17 fellowship trained rhinologists across Canada evaluated the 28 original statements on a scale of 1-10 and provided comments. A rating within 1-3 indicated disagreement, 8-10 demonstrated agreement and 4-7 represented being neutral towards a statement. All ratings were quantitively reviewed by mean, median, mode, range and standard deviation. Consensus was defined by removing the highest and lowest of the scores and using the "3 point relaxed system".

Results: After three rounds, a total of 11 statements achieved consensus. This white paper only contains the final agreed upon statements and clear rationale and support for the statements regarding the use of biologics in patients with CRS.

Conclusion: This white paper provides guidance to Canadian physicians on the use of biologic therapy for the management of patients with CRS, but the medical and surgical regimen should ultimately be individualized to the patient. As more biologics become available and additional trials are published we will provide updated versions of this white paper every few years.

Keywords: Biologics; Chronic Rhinosinusitis; Chronic rhinosinusitis with nasal polyposis; Type 2 inflammation.

PubMed Disclaimer

Conflict of interest statement

AT: Consultant: Olympus, Starfish Medical; Sanofi Advisory Board.

AJ: Advisory Board: Sanofi Genzyme, GSK; Consultant: SaNOtize Research and Development Corp., Ondine Biomedical, CoMotion Inc., iView Therapeutics; Speaker: Vertex Pharmaceuticals.

LS: Clinical trial support: GSK, Roche, AstraZeneca, Optinose; Honorarium/Advisory board: Sanofi, Mylan; Speaker fees: Medtronic, Mylan, Sanofi.

SK: Research Funding: CIHR (Canadian Institute of Health Research), Physician Services Incorporated (PSI), The Ottawa Hospital Academic Medical Organisation (TOHAMO).

Medtronic, Sanofi, AstraZeneca, Novartis, Roche / Genentech, GSK; Speaker: Mylan, Sanofi, ALK; Consultant: Sanofi.

DS: Industry sponsored research: GSK; Advisory board: Sanofi; Speaking fees: Medtronic.

BR: Consultant: Stryker, Trudell Medical and Smith & Nephew.

MT: Industry sponsored research: Sanofi and AstraZeneca; Consultant: Sanofi, AstraZeneca, and Novartis.

IW: Shareholder: Proteocyte Diagnostics Inc.; Consultant: Sanofi Genzyme, GSK.

JS, KS, JL: Advisory Board: Sanofi.

CC, EW, AJ, EM, YC, MD: None.

References

1. Desrosiers M, Evans GA, Keith PK, et al. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. All Asth Clin Immun. 2011;7:2. doi: 10.1186/1710-1492-7-2. - DOI - PMC - PubMed
1. Tait S, Kallogjeri D, Suko J, Kukuljan S, Schneider J, Piccirillo JF. Effect of budesonide added to large-volume, low-pressure saline sinus irrigation for chronic Rhinosinusitis: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2018;144(7):605–612. doi: 10.1001/jamaoto.2018.0667. - DOI - PMC - PubMed
1. Palmer JN, Jacobson KW, Messina JC, Kosik-Gonzalez C, Djupesland PG, Mahmoud RA. EXHANCE-12: 1-year study of the exhalation delivery system with fluticasone (EDS-FLU) in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2018;8:869–876. doi: 10.1002/alr.22141. - DOI - PMC - PubMed
1. Stein NR, Jafari A, DeConde AS. Revision rates and time to revision following endoscopic sinus surgery: a large database analysis. Laryngoscope. 2018;128(1):31–36. doi: 10.1002/lary.26741. - DOI - PMC - PubMed
1. Hopkins C, Slack R, Lund V, Brown P, Copley L, Browne J. Long-term outcomes from the English national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Laryngoscope. 2009;119:2459–2465. doi: 10.1002/lary.20653. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- Xenbase

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis

Affiliations

Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Miscellaneous